Last reviewed · How we verify
Irinotecan liposome combined with bevacizumab
Irinotecan liposome combined with bevacizumab is a Small molecule drug developed by Zhifeng Tian,MD. It is currently in Phase 2 development.
At a glance
| Generic name | Irinotecan liposome combined with bevacizumab |
|---|---|
| Sponsor | Zhifeng Tian,MD |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Liposomal Irinotecan in Combination With Temozolomide and Bevacizumab in Patients With Advanced STS (PHASE2)
- Intraperitoneal Injection of Liposomal Irinotecan as Monotherapy or in Combination With Recombinant Mutant Human Tumor Necrosis Factor or Bevacizumab for the Treatment of Malignant Ascites Following Failure of Prior Standard Therapy (PHASE1, PHASE2)
- A Clinical Study on the Treatment of Metastatic Colorectal Cancer at the Second-line or Beyond. (PHASE2)
- Clinical Study of Second-line Treatment in Advanced Colorectal Cancer With Chemotherapy With Bevacizumab or Cetuximab (PHASE2)
- Hypofractionated Radiotherapy Combined With NALIRIF, PD-1 Antibody in Locally Recurrent Rectal Cancer(NOVELTY-R) (PHASE2)
- A Study on the Efficacy and Safety of Irinotecan Liposome (II), 5-FU/LV in Combination With Bevacizumab for the Treatment of Advanced Colorectal Cancer (PHASE2)
- Fruquintinib vs Bevacizumab Combined With Irinotecan Liposome and Capecitabine as Second-Line Therapy for Advanced Metastatic Colorectal Cancer (PHASE2)
- Liposomal Irinotecan (II) Fractionated Dosing Combined With 5-FU/LV (FOLFIRInali-3) and Bevacizumab in Second-line Treatment of Advanced Colorectal Cancer: A Single-arm, Phase II Clinical Study (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Irinotecan liposome combined with bevacizumab CI brief — competitive landscape report
- Irinotecan liposome combined with bevacizumab updates RSS · CI watch RSS
- Zhifeng Tian,MD portfolio CI
Frequently asked questions about Irinotecan liposome combined with bevacizumab
What is Irinotecan liposome combined with bevacizumab?
Irinotecan liposome combined with bevacizumab is a Small molecule drug developed by Zhifeng Tian,MD.
Who makes Irinotecan liposome combined with bevacizumab?
Irinotecan liposome combined with bevacizumab is developed by Zhifeng Tian,MD (see full Zhifeng Tian,MD pipeline at /company/zhifeng-tian-md).
What development phase is Irinotecan liposome combined with bevacizumab in?
Irinotecan liposome combined with bevacizumab is in Phase 2.